聚乙二醇干扰素α-2a联合胸腺肽α1治疗慢性乙型肝炎的临床研究  

Clinical Study of PEG-IFN alpha-2a with Thymosin α1 in Treatment of Chronic Hepatitis B

作　　者：张国顺[1] 尚华[2] 马利转 张超[1] 王玉兰[1] 李玉林[1] 

机构地区：[1]华北煤炭医学院附属医院消化内科,河北省唐山市063000 [2]唐山市传染病院

出　　处：《中国全科医学》2010年第25期2818-2820,共3页Chinese General Practice

基　　金：唐山市科技攻关指令项目(081302010)

摘　　要：目的探讨聚乙二醇干扰素α-2a(PEG-IFNα-2a)联合胸腺肽α1治疗慢性乙型肝炎的临床疗效。方法将83例CHB患者随机分为A、B两组,A组PEG-IFNα-2a联合胸腺肽α1治疗,B组单独使用PEG-IFNα-2a,对治疗前后肝组织学、血清HBsAg、HBeAg、HBVDNA等指标的变化进行观察。结果治疗组患者6个月时的血清ALT、AST复常率显著高于对照组,两者比较差异有统计学意义(P<0.05)。治疗组患者治疗6、9、12个月时HBsAg、HBeAg及HBVDNA转阴率与对照组比较均降低,两组比较HBsAg、HBVDNA转阴率差异有统计学意义(P<0.05)。两组患者肝组织病理肝细胞炎症及纤维化程度较治疗前明显减轻,两组比较差异有统计学意义(P<0.05)。结论 PEG-IFNα-2a联合胸腺肽α1治疗CHB疗效优于单一使用PEG-IFNα-2a。Objective To study the clinical efficacy of PEG-IFNα-2a combined with thymosin α1 in treatment of chronic hepatitis B.Methods Totally 83 patients with chronic hepatitis B were randomly divided into two groups （A,B）.The patients in the group A （n=42） were treated with PEG-IFN α-2a and thymosin α1;while the patients in the group B （n=41） were treated with PEG-IFNα-2a only.The changes in liver histopathology and the serum levels of HBsAg,HBeAg,HBV DNA were studied before and after the treatment.Results The recovery rates of serum levels of alanine aminotransferase （ALT） and Aspartate aminotransferase （AST） were significantly higher in the group A than in the group B after 6-month treatment （P0.05）.The negative conversion ratios of HBsAg and HBVDNA were significantly higher in the group A than in the group B after 6-,9-and 12-month treatment （P0.05）.The grades of histological hepatocyte inflammation and hepatitic fibrosis were significantly lower in the group A than in the group B after treatment （P0.05）.Conclusion PEG-IFNα-2a combined with thymosin α1 is more effective than PEG-IFNα-2a alone for treating patients with chronic hepatitis B.

关 键 词：肝炎 乙型 慢性 聚乙二醇干扰素Α-2A 胸腺肽Α1 

分 类 号：R512.62[医药卫生—内科学]